MoonLake Immunotherapeutics
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jorge Santos da Silva
- Full Time Employees
- 130
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Dorfstrasse 29 Zug ZG Switzerland 6300
- IPO Date
- Oct 20, 2020
- CIK
- 0001821586
- Website
- moonlaketx.com
- Similar Companies
- Business
- MoonLake Immunotherapeutics (NASDAQ:MLTX), a clinical-stage biopharmaceutical company founded in 2021 and headquartered in Zug, Switzerland, focuses on developing next-generation Nanobody therapies targeting inflammatory skin and joint diseases driven by interleukins IL-17A and IL-17F; its lead candidate, Sonelokimab (SLK), is a novel tri-specific Nanobody that inhibits IL-17A/A, IL-17A/F, and IL-17F homodimers, advancing in Phase 3 trials including VELA-1 (NCT06411899) and VELA-2 (NCT06411379) for hidradenitis suppurativa (HS) in adults, VELA-TEEN for adolescent HS, and IZAR-1 (NCT06641076) and IZAR-2 (NCT06641089) for psoriatic arthritis (PsA), alongside Phase 2 programs such as LEDA for palmoplantar pustulosis (PPP), S-OLARIS for axial spondyloarthritis (axSpA), and P-OLARIS for PsA with axSpA overlap, with Phase 3-ready status for psoriasis (PsO). The company conducts global clinical trials to address unmet needs in dermatology and rheumatology patient populations. Recent developments include completion of enrollment in the Phase 3 VELA HS program with week-16 results reported in late 2025 prompting investor scrutiny and securities investigations, initiation of three new sonelokimab trials in early 2025 for adolescent HS, PPP, and axSpA, a $500 million non-dilutive financing agreement with Hercules Capital including $75 million drawn to fund operations through a potential 2027 launch, a three-year technology partnership with Komodo Health, and a $75 million offering to support sonelokimab research.
MoonLake Immunotherapeutics Target of Unusually High Options Trading (NASDAQ:MLTX)
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
Arrowstreet Capital Limited Partnership Acquires New Shares in MoonLake Immunotherapeutics $MLTX
Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?
MoonLake Immunotherapeutics' CFO Sells 39K Shares
MoonLake: 'Buy' Sonelokimab BLA Submission HS September And Label Expansion
Why MoonLake Immunotherapeutics Stock Wilted on Wednesday
MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering
MoonLake Immunotherapeutics: Label Upside Drives The Next Leg Higher
MoonLake Immunotherapeutics Announces Proposed Public Offering
MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript
MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
MoonLake Immunotherapeutics CFO Trims His Stake. Should Investors Be Concerned?
FDA Aligns With MoonLake On Lead Drug Submission Plans, Stock Soars
MoonLake Clears A Key Regulatory Hurdle, And Shares Rocket
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?
Da Silva Jorge Santos Sells 98,127 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 6% – Should You Sell?